SCHEMBL24664403

SCHEMBL24664403

CC(C)Cc1ccc2cn(C)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
KDM4E B2RXH2 2/20 0.53
NSD2 O96028 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KDM4C Q9H3R0 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
NOTUM Q6P988 1/20 0.36
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
ABL1 P00519 1/20 0.34
PARP14 Q460N5 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
SCD5 Q86SK9 1/20 0.33
KIT P10721 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20018578 0.87 KDM4E (0.43) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL22331110 0.82 NOTUM (0.40) MAPTKDM4ENSD2ALDH1A1GABRA1
SCHEMBL12729869 0.81 KDM4E (0.58) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL3436679 0.79 MAPT (0.56) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL18339237 0.79 MAPT (0.56) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL904782 0.79 MAPT (0.61) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL30570094 0.77 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL30570132 0.77 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL19539242 0.75 MAPT (0.39) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL28265750 0.74 MAPT (0.50) MAPTKDM4ENSD2ALDH1A1KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL MAPT 370/4885KDM4E 2617/4885NSD2 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.